Patients and Methods. Peritoneal tumor tissue from 15appendiceal and 8 colon cancer patients who underwentCRS/HIPEC were used for personalized organoid development. Organoids were perfused in parallel at 37 and 42℃with low- and high-dose oxaliplatin (200 mg/㎡ over 2 h vs. 460 mg/㎡ over 30 min) and MMC (40 mg/3L over 2 h). Viability assays were performed and pooled for statistical analysis.